Try GOLD - Free
Prediabetes can significantly impact quality of life
BioSpectrum Asia
|November 2023
Even though prediabetes is a leading risk factor for diabetes and may predict cardiovascular disease and increased mortality, the degree of unawareness is very high with up to 85 per cent not being aware of their condition. Early diagnoses can help enable better treatment outcomes, better quality of life, and damaged nerves can be regenerated if nerve care damage has not progressed too far.
The term "prediabetes" refers to a glycemic state not yet exceeding the diagnostic threshold for diabetes and, thus, not yet considered 'diabetic'. Nevertheless, a person with prediabetes already shows signs of impaired glucose tolerance (IGT) and blood glucose levels slightly above normoglycemia.
1. Prediabetes usually progresses to diabetes but can fully resolve with appropriate lifestyle interventions.
2. Often, people with prediabetes do not have clear signs or symptoms and are therefore often not aware of their condition. However, severe complications such as nerve damage, leading to a disease called peripheral neuropathy (PN), can also develop within these patients already. Symptoms of peripheral neuropathy include numbness, tingling, prickling, and burning sensations in the hands and feet. Besides prediabetes, diabetes mellitus and B vitamins deficiencies are other high-risk factors leading to peripheral nerve damage, this risk is growing with increasing age. Further, B vitamins deficiency is highly prevalent in Diabetes patients (B1: 98 per cent; B6: 63 per cent; B12: up to 19 per cent)
Global prevalence
This story is from the November 2023 edition of BioSpectrum Asia.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM BioSpectrum Asia
BioSpectrum Asia
There are talent shortages in specialised modalities such as ADCs, peptides, and computational biology
As the Asia Pacific (APAC) contract development and manufacturing organisation (CDMO) sector continues to expand rapidly due to rising R&D investment, strong biotech formation, increased demand for Investigational New Drug (IND) - enabling and early Chemistry, Manufacturing, and Controls (CMC) services, and national incentives for biomanufacturing, KBI Biopharma is focused on targeted expansion into Japan, Korea, Taiwan, and Australia, for improving local engagement and enhancing access to global network. BioSpectrum Asia spoke to Katie Edgar, Chief Business Officer, KBI Biopharma to learn more about the company's growth plans in 2026, and about the growth opportunities in store for the CDMO market within the APAC region.
4 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
WHO and the European Commission expand partnership to combat AMR
The World Health Organization (WHO) and the European Commission's Health Emergency Preparedness Authority (HERA) have signed a €3.5 million agreement to expand their partnership to combat antimicrobial resistance (AMR) under the EU4Health programme.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Reshaping Asia's Healthcare with mRNA Innovation
The COVID-19 pandemic acted as both a challenge and a catalyst, serving as a testbed that fundamentally reshaped the biotechnology landscape across Asia and beyond. What emerged during this period was not just a breakthrough moment for mRNA, but the early foundation of a broader transformation that is still unfolding.
2 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Japan Pushes Startups to Power the Next Biotech Cycle
In recent years, the Japanese government has rolled out a series of initiatives to reshape the country's biopharma ecosystem. These include expanded venture funding, targeted subsidies for drug development, and tax incentives for investors, entrepreneurs, and startup employees.
4 mins
BioSpectrum Asia Jan 2026
BioSpectrum Asia
PRISM BioLab partners with Talus Bioscience for AI-based drug discovery
Japan-based PRISM BioLab and US-based startup Talus Bioscience, Inc. have entered into a collaboration to discover novel inhibitors of transcription factor (TF) and protein-protein interaction (PPI) targets.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Ferronova raises $6 M to advance imageguided cancer surgery
Australian startup Ferronova has raised a further $6 million to progress the commercialisation of a novel nanoparticle image-guided surgery solution seeking to improve identification of cancer cells and reduce the risk of undetected recurrence following surgery.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
PAHO launches roadmap to improve blood pressure control
The Pan American Health Organization (PAHO) has launched the new HEARTS Quality Framework, a practical guide published in The Lancet Regional Health - Americas, which countries can immediately use to enhance hypertension and cardiovascular risk management, prevent heart attacks and strokes, and deliver better care through primary health care within their communities.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
UK and Singapore launch new regulatory innovation corridor to fast-track health technologies
As part of this first-of-its-kind partnership between the UK's Medicines and Healthcare products Regulatory Agency (MHRA) and Singapore's Health Sciences Authority (HSA), companies will have a coordinated fast track pathway to engage both regulators at the same time.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Zydus Lifesciences partners with Myriad Genetics to launch cancer-risk assessment diagnostic tests in India.
India-based Zydus Lifesciences has signed an agreement with US-based Myriad Genetics, a leader in molecular diagnostic testing and precision medicine.
1 min
BioSpectrum Asia Jan 2026
BioSpectrum Asia
Korea steps up pandemic response with $18.9 M investment in CEPI
The Republic of Korea has announced new $18.9 million support to bolster national and global efforts to protect against the next deadly pandemic and boost international health security.
1 min
BioSpectrum Asia Jan 2026
Translate
Change font size
